# Study of Monoclonal Antibodies for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus

> **NCT05729360** · PHASE2 · UNKNOWN · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 30 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** GamCoviMab

## Key facts

- **NCT ID:** NCT05729360
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05729360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05729360, "Study of Monoclonal Antibodies for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05729360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*